Joshua Disbrow
CEO & Director
I am Josh Disbrow Co-Founder and Chief Govt Officer of Aytu. And it is my pleasure to welcome you to Aytu Biopharma’s first ever Investor Day. Welcome to all these right here becoming a member of us in-person in New York Metropolis, and welcome additionally to all of these becoming a member of through the webcast, nice to have you ever all right here. It is an thrilling day for Aytu having simply introduced the formal and official launch of Exxua simply this morning previous to the market open, actually an exhilarating time within the firm’s historical past as we take a look at this transformational time and this transformational alternative that we’ve as we take into consideration the launch of Exxua, the primary and solely 5-HT1a agonist and really a first-in-class remedy for main depressive dysfunction.
Excited to let you realize that we’re — we have the gross sales pressure now totally deployed. We’re truly on the market producing prescriptions as we converse, having already generated a big variety of prescriptions and listening to a variety of enthusiasm from the sector. It is really a singular alternative for us as Aytu as we take into consideration the chance that’s Exxua.
Earlier than we get began, some housekeeping gadgets and the compulsory forward-looking statements. Only a reminder that a few of us that will probably be talking at the moment could also be making some forward-looking statements as we progress via the dialogue.
Additional, I am going to refer you to Aytu Biopharma’s
